We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+9.36%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$377M
AUM Growth
-$132M
Cap. Flow
-$52M
Cap. Flow %
-13.79%
Top 10 Hldgs %
59.97%
Holding
58
New
11
Increased
13
Reduced
12
Closed
14

Top Buys

Rank Stock Value
1
TARA icon
Protara Therapeutics
TARA
+$64.2M
2
ETON icon
Eton Pharmaceutcials
ETON
+$12.7M
3
MTEM
Molecular Templates, Inc.
MTEM
+$7.79M
4
MYOV
Myovant Sciences Ltd.
MYOV
+$7.36M
5
KALA icon
KALA BIO
KALA
+$5M

Top Sells

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$34.1M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$21.2M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$17.5M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$13.9M
5
AXGN icon
Axogen
AXGN
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.07%
2 Miscellaneous 1.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZYME icon
26
Zymeworks
ZYME
$2.07B
$4.72M 1.25%
133,000
-42,000
-24% -$1.72M
TCDA
27
DELISTED
Tricida, Inc. Common Stock
TCDA
$4.27M 1.13%
194,000
– –
CPRX
28
DELISTED
Catalyst Pharmaceutical
CPRX
$4.04M 1.07%
+1,050,000
New +$4.31M
VSTM icon
29
Verastem
VSTM
$668M
$3.87M 1.02%
+121,992
New +$3.06M
DNTH icon
30
Dianthus Therapeutics
DNTH
$6.24B
$2.73M 0.72%
27,170
-952
-3% -$176K
NERV icon
31
Minerva Neurosciences
NERV
$245M
$2.71M 0.72%
+56,263
New +$3.39M
MGNX icon
32
MacroGenics
MGNX
$260M
$2.46M 0.65%
422,300
+221,800
+111% +$2.01M
CDTX
33
DELISTED
Cidara Therapeutics
CDTX
$2.25M 0.6%
+45,303
New +$2.71M
FLXN
34
DELISTED
Flexion Therapeutics, Inc.
FLXN
$2.22M 0.59%
281,600
-133,900
-32% -$2.02M
RDUS
35
DELISTED
Radius Health, Inc.
RDUS
$2.17M 0.58%
167,000
-1,000
-0.6% -$17.8K
AMRN
36
Amarin Corp
AMRN
$297M
$1.82M 0.48%
22,750
-10,500
-32% -$3.49M
KALV
37
DELISTED
KalVista Pharmaceuticals
KALV
$1.72M 0.46%
+225,000
New +$3.04M
PRVB
38
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$1.53M 0.4%
+166,000
New +$2.14M
RNAC icon
39
Cartesian Therapeutics
RNAC
$302M
$940K 0.25%
+13,000
New +$1.26M
TELA icon
40
TELA Bio
TELA
$29.2M
$633K 0.17%
81,000
-94,000
-54% -$1.27M
ACAD icon
41
Acadia Pharmaceuticals
ACAD
$5.12B
$63K 0.02%
1,500
-205,000
-99% -$8.45M
OCUL icon
42
CALL
Ocular Therapeutix
OCUL
$2.38B
$53K 0.01%
+1,000
New +$4.94K
BLRX
43
BioLineRX
BLRX
$12.1M
$22K 0.01%
417
– –
AQST icon
44
Aquestive Therapeutics
AQST
$648M
– –
-738,500
Closed -$4.3M
AXGN icon
45
Axogen
AXGN
$2.78B
– –
-700,000
Closed -$12.5M
BPMC
46
DELISTED
Blueprint Medicines
BPMC
– –
-100,000
Closed -$8M
FENC icon
47
Fennec Pharmaceuticals
FENC
$413M
– –
-12,000
Closed -$78K
PTCT icon
48
PTC Therapeutics
PTCT
$5.99B
– –
-191,000
Closed -$9.17M
QTRX icon
49
Quanterix
QTRX
$125M
– –
-132,200
Closed -$3.12M
RYTM icon
50
Rhythm Pharmaceuticals
RYTM
$7.75B
– –
-110,500
Closed -$2.54M
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2020 Portfolio in Review

As of Q1 2020, Opaleye Management held 58 positions worth $377M, down 26% from $510M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Opaleye Management withdrew a net $52M in Q1 2020, closing 14 positions and reducing 12 holdings. Its most notable exit was Epizyme, Inc, an estimated $34.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Molecular Templates, Inc. worth $7.09M.

  • Opaleye Management's largest Q1 2020 buy was Molecular Templates, Inc.: 35,560 shares worth $7.09M.
  • Opaleye Management added most to Protara Therapeutics in Q1 2020, an estimated $64.2M increase.
  • Opaleye Management's biggest Q1 2020 reduction was Forty Seven, Inc. Common Stock, cutting an estimated $10.7M.
  • Opaleye Management fully exited Epizyme, Inc in Q1 2020, selling an estimated $34.1M.
  • Opaleye Management's ten largest holdings make up 60% of its $377M portfolio in Q1 2020.
  • Opaleye Management opened 11 new positions and closed 14 in Q1 2020.
  • Opaleye Management's portfolio value fell 26% quarter-over-quarter to $377M.

Based on Opaleye Management's 13F filing for Q1 2020, filed 15 May 2020.